Staying ahead of the technology curve means strengthening your competitive advantage. That is why we give you data-driven innovation insights into the healthcare sector. This time, you get to discover 5 hand-picked startups developing prognostics solutions.
Global Startup Heat Map: 5 Top Prognostics Solutions for Healthcare
The 5 prognostics startups you will explore below are chosen based on our data-driven startup scouting approach, taking into account factors such as location, founding year, and relevance of technology, among others. This analysis is based on the Big Data & Artificial Intelligence (AI)-powered StartUs Insights Discovery Platform, covering over 1.3 million startups & scaleups globally.
The Global Startup Heat Map below highlights the 5 prognostics solutions for healthcare our Innovation Researchers curated for this report. Moreover, you get insights into regions that observe a high startup activity and the global geographic distribution of the 151 companies we analyzed for this specific topic.
Click to download
PredictImmune enables Patient Stratification
For doctors, it is often a challenge to determine the aggressiveness rate of therapy for a patient. While an aggressive therapy acts as overkill for a low-risk patient and may have side effects, a less aggressive therapy for a high-risk patient is ineffective. Prognostics solutions allow for patient stratification to determine the risk to the patients. This enables physicians to optimize the timing and approach for therapies.
British startup PredictImmune offers personalized treatment for immune-mediated diseases. PredictSURE IBD, the startup’s prognostic test for irritable bowel syndrome (IBS) diseases, uses quantitative reverse transcription-polymerase chain reaction (RT-qPCR) to measure gene expression in whole blood samples. It stratifies adult patients by risk of early and frequent relapses to determine the right treatment for them.
Neurognos provides Neurodegenerative Disease Detection
Alzheimer’s is a neurodegenerative disease that frequently incurs cognitive challenges like memory loss and short attention span in elderly patients. A lot of patients are diagnosed in later stages when treatment generally hardly works. However, the onset of disease at the molecular level generally occurs long before any visible symptoms occur. Startups are developing AI-based solutions to provide an accurate prognosis for the disease.
Chilean startup Neurognos provides solutions to detect neurodegenerative diseases. The startup’s proprietary technology enables the identification of early indications of Alzheimer’s disease. It uses machine learning (ML) algorithms to detect disease-associated patterns in biomarkers. The solution pinpoints the signs of disease even years before any cognitive symptoms show up.
Dicronis develops a Lymphatic Tracker
Secondary lymphedema is a common side effect after surgeries, traumas, infections, inflammations, or radiotherapies. Current diagnostics methods are not reliable enough and detect lymphedema only in advanced stages. Startups are developing wearables to offer better lymphatic function prognosis. By allowing doctors to perform effective interventions, improves the therapeutic outcome and quality of life of the patients.
Dicronis is a Swiss startup developing a home-based lymphatic tracker. Lymphit, the startup’s device, combines microarray patches that deliver a fluorescent agent to the skin, and an optical wearable. The optical unit measures changes in the intensity of fluorescence as a proxy for lymphatic drainage efficiency. Lymphit helps doctors remotely monitor lymphatic function, enabling prognosis before limb swelling is visible.
Delee detects Circulating Tumor Cells (CTCs)
CTCs represent cancer cells from primary tumors or metastasized cells circulating in peripheral blood and, therefore, early indicators of cancers. Solutions that detect circulating tumor cells generally involve enrichment with antibodies. However, there are no universal markers that are present in all types of cancers. Healthcare startups are working on liquid biopsy solutions for more effective cancer prognosis.
Delee is a US-based startup that develops a platform to detect circulating tumor cells. CytoCatch, the startup’s liquid biopsy solution, automates the isolation, preparation, and analysis of CTCs. The startup’s technology uses AI and an imaging system to enumerate and classify CTCs. It facilitates early detection of cancer, as well as monitoring of disease progression and evaluating of therapies effectiveness.
Perceiv AI offers Clinical Trial Prognosis
Patients with untreatable conditions often opt for experimental therapies. Pharma and biotech companies, on the other hand, find it hard to identify the right patients for clinical trials. Prognostics enables clinical trial managers to find the right patient subgroups for effective trials. These solutions are increasingly turning to AI to derive insights from biomedical data and patient reports.
Canadian startup Perceiv AI offers a clinical trial prognosis for precision medicine. The startup uses multimodal data sources and digital biomarkers to identify patients for an experimental treatment. The product allows for precise targeting of patient subgroups in large, heterogeneous populations. By enabling richer insights from clinical trials, the solution reduces the cost and duration of clinical trials.
Discover more Healthcare Startups
To keep you up-to-date on the latest technology and emerging solutions, we provide you with actionable innovation intelligence – quickly and exhaustively. You can download our free Healthcare Innovation Report and discover new business opportunities or save your time & let us look into your areas of interest. We provide you with an exhaustive overview of new startups, scaleups & emerging technologies that matter to you.
